跳至主要内容
临床试验/NCT00749424
NCT00749424已完成4 期

CORONARY BIFURCATIONS: APPLICATION OF THE CRUSHING TECHNIQUE USING SIROLIMUS-ELUTING STENTS - The "CACTUS" Trial

Cordis Corporation2 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2004年1月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
350
试验地点
2
主要终点
Major Adverse and Cardiac Events (MACE)

研究概览

简要总结

The objective of this study is to compare the safety and effectiveness of two different approaches to treat bifurcational lesions with CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent , Cordis Corp): a) the "crushing" technique to stent both branches vs. b) a provisional T stenting technique of the side branch.

详细描述

This is a prospective, randomized study that will be conducted at up to 5 centers in Italy. All patients who meet the eligibility criteria will be treated with the Cypher SelectTM Stent and Stent Delivery System (SDS). Patients will have repeat angiography at six months, with clinical follow-up to 2 years.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Is a male or non-pregnant female patient >= 18 years of age [NOTE: Females of child-bearing potential must have a negative pregnancy test];
  • Has a diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR has documented silent ischemia;
  • Has at least TIMI I coronary flow in both the main and side branches;
  • Involves a single treatment of a de novo bifurcation lesion in native coronary arteries of patients with single or multivessel disease; patients with multiple lesions can be included only if other lesions treated during the index procedure are successfully treated prior to the treatment of the bifurcation lesion;
  • Has a true bifurcation lesion defined as stenosis > 50% in both the main branch and the ostium of the side branch;
  • Has a maximum treatable main or side branch lesion length <=28 mm;
  • Has a main branch vessel that is >= 2.5 mm and <= 3.5 mm in diameter by on-line QCA proximal to the bifurcation;
  • Has a side branch vessel that is >= 2.25 mm and <= 3.5 mm in diameter by on-line QCA;
  • Is an acceptable candidate for coronary artery bypass surgery (CABG);
  • Is willing to comply with the specified follow-up evaluation;
  • The patient or legally authorized representative must provide written informed consent prior to the procedure.

排除标准

  • Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented elevation of CK levels > 2 times normal or CK-MB levels > 3 times normal within the preceding 24 hours and/or the CK and CK-MB enzymes remain above normal at the time of treatment;
  • Has unstable angina classified as Braunwald A I-III, B&C III;
  • Has a bifurcation lesion in a non protected left main;
  • Has an ejection fraction <= 35%;
  • Has known allergies to the following: aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or sirolimus;
  • Has a known serious allergy to contrast media or stainless steel that cannot be managed medically;
  • Has impaired renal function (creatinine > 3.0 mg/dl);
  • There is presence of thrombus in the bifurcation lesion;
  • Has a target lesion with excessive tortuousity unsuitable for stent delivery and deployment;
  • Has a totally occluded vessel;
  • Is the recipient of a heart transplant;
  • Has a significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
  • Is currently participating in an investigational drug or another device study.

结局指标

主要结局

Major Adverse and Cardiac Events (MACE)

时间窗: 6 and 12 months post-procedure

次要结局

  • Minimal lumen diameter (MLD)(6 months)
  • Percent diameter stenosis (%DS)(6 months)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验